Two leading medical organizations say that using a human papillomavirus (HPV) test alone for cervical cancer screening is an effective alternative to the current recommendation for screening with either cytology (the Pap test) alone or co-testing with cytology and HPV testing.
The Society of Gynecologic Oncology (SGO) and the American Society for Colposcopy and Cervical Pathology (ASCCP) issued an interim guidance report after the Food and Drug Administration (FDA) approved the cobas® HPV test as a “primary,” or first, test performed for cervical cancer screening. The test detects DNA from 14 high-risk HPV types, including types 16 and 18, which are responsible for 70 percent of cervical cancers. The guidance report is being jointly published online on Jan. 8 by Gynecologic Oncology, the Journal of Lower Genital Tract Disease, and Obstetrics and Gynecology.
The report, “Use of Primary High Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance,” will help doctors and other clinical providers determine how best to integrate primary HPV testing into the care of their patients until several medical societies update their evidence-based guidelines for cervical cancer screening.
Cervical cytology, frequently called the “Pap” test, can detect abnormal cells in the cervix that could be pre-cancerous; follow-up and management leads to prevention of invasive cancer. Its widespread use in the U.S. is credited with greatly reducing both the occurrence of and deaths from cervical cancer.
As investigators learned about the role HPV plays in the development of cervical cancer, tests to detect the virus were developed and used in conjunction with cytology. Many studies now show that HPV testing may be more effective than cytology alone in detecting cervical pre-cancer.
“Our review of the data indicates that primary HPV testing misses less pre-cancer and cancer than cytology alone. The guidance panel felt that primary HPV screening can be considered as an option for women being screened for cervical cancer,” says Warner K. Huh, MD, division director and professor in the Division of Gynecologic Oncology at the University of Alabama, Birmingham. Huh is a spokesperson for the SGO and lead author of the interim guidance report.
The report recommends:
- Primary HPV testing can be considered for women starting at age 25.
- Women under age 25 should continue to follow current guidelines that recommend cytology alone beginning at age 21.
- Women with a negative primary HPV test result should not be retested again for three years. This is the same screening interval recommended under current guidelines for a normal cytology test result.
- An HPV test positive for HPV 16 and 18, two types associated with a higher risk of future disease, should be followed with colposcopy, a test that allows the doctor to examine the cervix under illumination and magnification.
- A test that is positive for HPV types other than 16 and 18 should be followed by reflex cytology testing.
In developing the guidance report, the medical societies reviewed 11 studies, including “Primary Cervical Cancer Screening with Human Papillomavirus: End of Study Results from the ATHENA Study Using HPV as the First-Line Screening Test,” also published Jan. 8 in Gynecologic Oncology. This U.S. study demonstrated that primary HPV screening is an effective screening strategy in women 25 years and older. The authors of the guidance report noted the need for additional studies to further define the role of primary HPV screening and its integration with other existing guidance on screening for cervical cancer, and managing abnormal screening tests and diagnosed cervical pre-cancer.
“The introduction of cervical cytology screening was truly one of the great breakthroughs in medicine, and has saved countless lives,” says ASCCP’s chief medical officer Herschel Lawson, MD. “We are lucky that we have so many tools available now to improve cervical cancer prevention efforts and afford patients options depending on their individual situations. We’ll continue to work to find the best way to combine screening tools with other prevention efforts like HPV vaccines, for the early detection and treatment of cervical cancer.
“The most important message for providers and the community is that women should be screened for cervical cancer,” Lawson adds. “Screening saves lives.”
Source: Society of Gynecologic Oncology
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.